相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。NRG/RTOG 1112: Randomized phase III study of sorafenib vs. stereotactic body radiation therapy (SBRT) followed by sorafenib in hepatocellular carcinoma (HCC).
Laura A. Dawson et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
High-Dose Once-Daily Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538
Jeffrey Bogart et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
Using and Understanding Survival Statistics- or How We Learned to Stop Worrying and Love the Kaplan-Meier Estimate
Soren M. Bentzen et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2023)
The MaxCombo Test Severely Violates the Type I Error Rate
Dominic Magirr et al.
JAMA ONCOLOGY (2023)
Assessment of Median and Mean Survival Time in Cancer Clinical Trials
Ananya Das et al.
JAMA NETWORK OPEN (2023)
Review of Clinical Equipoise: Examples from Oncology Trials
Majd A. A. AlHamaly et al.
CURRENT REVIEWS IN CLINICAL AND EXPERIMENTAL PHARMACOLOGY (2023)
Bayesian interpretation of immunotherapy trials with dynamic treatment effects
Eduardo Castanon et al.
EUROPEAN JOURNAL OF CANCER (2022)
The radiotherapy quality assurance gap among phase III cancer clinical trials
Kelsey L. Corrigan et al.
RADIOTHERAPY AND ONCOLOGY (2022)
Association between Prior Malignancy Exclusion Criteria and Age Disparities in Cancer Clinical Trials
Roshal R. Patel et al.
CANCERS (2022)
Understanding the Differences Between Bayesian and Frequentist Statistics
Isabella Fornacon-Wood et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2022)
Post-protocol therapy and informative censoring in the CANDOR study
Tomer Meirson et al.
LANCET ONCOLOGY (2022)
Incidence and impact of proportional hazards violations in phase 3 cancer clinical trials.
Timothy Lin et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Testing for Differences in Survival When Treatment Effects Are Persistent, Decaying, or Delayed
John O'Quigley
JOURNAL OF CLINICAL ONCOLOGY (2022)
Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials A Systematic Review and Meta-analysis
Pralay Mukhopadhyay et al.
JAMA ONCOLOGY (2022)
Interpreting the results of noninferiority trials-a review
Jack Cuzick et al.
BRITISH JOURNAL OF CANCER (2022)
Handling Informative Premature Treatment or Study Discontinuation for Assessing Between-Group Differences in a Comparative Oncology Trial
Bo Huang et al.
JAMA ONCOLOGY (2022)
Handling Informative Premature Treatment or Study Discontinuation for Assessing Between-Group Differences in a Comparative Oncology Trial
Bo Huang et al.
JAMA ONCOLOGY (2022)
The Bayesian Design of Adaptive Clinical Trials
Alessandra Giovagnoli
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2021)
Detecting the Dark Matter of Unpublished Clinical Cancer Studies: An Analysis of Phase 3 Randomized Controlled Trials
Dario Pasalic et al.
MAYO CLINIC PROCEEDINGS (2021)
Assessment of Treatment Effects and Long-term Benefits in Immune Checkpoint Inhibitor Trials Using the Flexible Parametric Cure Model A Systematic Review
Thomas Filleron et al.
JAMA NETWORK OPEN (2021)
Food and Drug Administration approvals in phase 3 Cancer clinical trials
Joseph Abi Jaoude et al.
BMC CANCER (2021)
Informative censoring of surrogate end-point data in phase 3 oncology trials
Shai Gilboa et al.
EUROPEAN JOURNAL OF CANCER (2021)
Lessons Learned From Implementing a Novel Bayesian Adaptive Dose-Finding Design in Advanced Pancreatic Cancer
Rebecca S. S. Tidwell et al.
JCO PRECISION ONCOLOGY (2021)
Sex-Based Disparities Among Cancer Clinical Trial Participants
Ethan B. Ludmir et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2020)
Incidence and correlates of HIV exclusion criteria in cancer clinical trials
Ethan B. Ludmir et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019
Emerson Y. Chen et al.
JAMA INTERNAL MEDICINE (2020)
Fulvestrant plus capivasertib for metastatic breast cancer
Ethan B Ludmir et al.
LANCET ONCOLOGY (2020)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Precision oncology: the intention-to-treat analysis fallacy
Jason K. Sicklick et al.
EUROPEAN JOURNAL OF CANCER (2020)
Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trials
Dario Pasalic et al.
EUROPEAN JOURNAL OF CANCER (2020)
Performance Status Restriction in Phase III Cancer Clinical Trials
Joseph Abi Jaoude et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)
Progression-free survival in the ICON8 trial
Ethan B Ludmir et al.
LANCET (2020)
Trial Sponsorship and Time to Reporting for Phase 3 Randomized Cancer Clinical Trials
Timothy A. Lin et al.
CANCERS (2020)
Current status of Bayesian clinical trials for oncology, 2020
Martha Fors et al.
CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS (2020)
Estimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical Trials
Emerson Y. Chen et al.
JAMA INTERNAL MEDICINE (2019)
Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration
Talal Hilal et al.
JAMA ONCOLOGY (2019)
Deviation from the Proportional Hazards Assumption in Randomized Phase 3 Clinical Trials in Oncology: Prevalence, Associated Factors, and Implications
Rifaquat Rahman et al.
CLINICAL CANCER RESEARCH (2019)
Factors Associated With Age Disparities Among Cancer Clinical Trial Participants
Ethan B. Ludmir et al.
JAMA ONCOLOGY (2019)
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial
Anders Widmark et al.
LANCET (2019)
Adaptive platform trials: definition, design, conduct and reporting considerations The Adaptive Platform Trials Coalition
Derek C. Angus et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Quantifying the benefit of non-small-cell lung cancer immunotherapy
Ethan B. Ludmir et al.
LANCET (2019)
Current management of limited-stage SCLC and CONVERT trial impact: Results of the EORTC Lung Cancer Group survey
Antonin Levy et al.
LUNG CANCER (2019)
Association between progression-free survival and patients' quality of life in cancer clinical trials
Thomas J. Hwang et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Methods for Accommodating Nonproportional Hazards in Clinical Trials: Ready for the Primary Analysis?
Boris Freidlin et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology
Lisa M. Hess et al.
JOURNAL OF CANCER (2019)
When is crossover desirable in cancer drug trials and when is it problematic?
A. Haslam et al.
ANNALS OF ONCOLOGY (2018)
The Current Status of Drug Discovery and Development as Originated in United States Academia: The Influence of Industrial and Academic Collaboration on Drug Discovery and Development
Tohru Takebe et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2018)
Hazards of Hazard Ratios - Deviations from Model Assumptions in Immunotherapy
Brian M. Alexander et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
G. K. Abou-Alfa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Do Surrogate Endpoints Better Correlate with Overall Survival in Studies That Did Not Allow for Crossover or Reported Balanced Postprogression Treatments? An Application in Advanced NonSmall Cell Lung Cancer
Mahmoud Hashim et al.
VALUE IN HEALTH (2018)
Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour
Jianrong Zhang et al.
BMJ OPEN (2018)
Bayesian Analysis: Using Prior Information to Interpret the Results of Clinical Trials
Melanie Quintana et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial
Corinne Faivre-Finn et al.
LANCET ONCOLOGY (2017)
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Lesley Seymour et al.
LANCET ONCOLOGY (2017)
Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval
Vinay Prasad et al.
JAMA INTERNAL MEDICINE (2017)
The reproducibility of research and the misinterpretation of p-values
David Colquhoun
ROYAL SOCIETY OPEN SCIENCE (2017)
Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio
Kyongsun Pak et al.
JAMA ONCOLOGY (2017)
Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?
Robert Kemp et al.
BMC MEDICINE (2017)
Observer variability in RECIST-based tumour burden measurements: a meta-analysis
Soon Ho Yoon et al.
EUROPEAN JOURNAL OF CANCER (2016)
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
David Dearnaley et al.
LANCET ONCOLOGY (2016)
Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration's Approval of Oncology Drugs
Chul Kim et al.
MAYO CLINIC PROCEEDINGS (2016)
The STAMPEDE trial: paradigm-changing data through innovative trial design
Bradley C. Carthon et al.
TRANSLATIONAL CANCER RESEARCH (2016)
Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies
Hajime Uno et al.
ANNALS OF INTERNAL MEDICINE (2015)
A versatile test for equality of two survival functions based on weighted differences of Kaplan-Meier curves
Hajime Uno et al.
STATISTICS IN MEDICINE (2015)
Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis
Hajime Uno et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome
Patrick Royston et al.
BMC MEDICAL RESEARCH METHODOLOGY (2013)
The Clinical Viewpoint: Definitions, Limitations of RECIST, Practical Considerations of Measurement
Liza C. Villaruz et al.
CLINICAL CANCER RESEARCH (2013)
RTOG 0529: A Phase 2 Evaluation of Dose-Painted Intensity Modulated Radiation Therapy in Combination With 5-Fluorouracil and Mitomycin-C for the Reduction of Acute Morbidity in Carcinoma of the Anal Canal
Lisa A. Kachnic et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2013)
Utilizing the integrated difference of two survival functions to quantify the treatment contrast for designing, monitoring, and analyzing a comparative clinical study
Lihui Zhao et al.
CLINICAL TRIALS (2012)
Design Issues in Randomized Phase II/III Trials
Edward L. Korn et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Progression-Free Survival: Meaningful or Simply Measurable?
Christopher M. Booth et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Accelerated Approval of Oncology Products: The Food and Drug Administration Experience
John R. Johnson et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Long-Term Results of Hypofractionated Radiation Therapy for Breast Cancer
Timothy J. Whelan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Bayesian Statistics in Oncology A Guide for the Clinical Investigator
Michel Adamina et al.
CANCER (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal - A randomized controlled trial
Jaffer A. Ajani et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Blinded independent central review of progression-free survival in phase III clinical trials: Important design element or unnecessary expense?
Lori E. Dodd et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
A dirty dozen:: Twelve P-value misconceptions
Steven Goodman
SEMINARS IN HEMATOLOGY (2008)
Non-inferiority trials: design concepts and issues - the encounters of academic consultants in statistics
RB D'Agostino et al.
STATISTICS IN MEDICINE (2003)
分享论文
